Table 2.
Main results of CD19 CAR T studies on ALL.
| Author, reference | Institution | Costimulatory domain | Age (median, range) | Infused N | ORR % | CRS, % | Neurotoxicity, % | OS |
|---|---|---|---|---|---|---|---|---|
| Maude et al.15 | UPenn | 4-1BB | 14 years (5–60) | 30 | 90% | 100% (severe, 27%) | 43% | 78% at 6 months |
| Davila et al.16 | MSKCC | CD28 | 50 years (NA) | 16 | 88% | severe, 44% | Gr 3/4, 25% | NA |
| Lee et al.17 | NCI | CD28 | 15 years (5–27) | 21 | 67% | 76% (Gr 3/4, 29%) | 29% (Gr 3/4, 5%) | 52% at 12 months |
| Turtle et al.18 | FHCRC | 4-1BB | 40 years (20–73) | 30 | 93% | 83% | 50% (Gr 3/4, 50%) | NA |
| Gardner et al.19 | SCRI | 4-1BB | 12 years (1–25) | 43 | 93% | 93% (Gr 3/4, 23%) | 49% (Gr 3/4, 21%) | 69.5% at 12 months |
| Maude et al.20 | Novartis | 4-1BB | 11 years (3–23) | 751 | 81% | 77% | 40% (Gr 3/4, 13%) | 76% at 12 months |
| Park et al.21 | MSKCC | CD28 | 44 years (23–74) | 532 | 83% | 85% (Gr 3/4, 26%) | 48% (Gr 3/4, 42%) | median, 12.5 months |
1
Screened: 92; 2Screened: 75.
ALL, acute lymphoblastic leukemia; CAR-T, chimeric antigen receptor T; CRS, cytokine release syndrome; FHCRC, Fred Hutchinson Cancer Research Center; Gr, grade; MSKCC, Memorial Sloan Kettering Cancer Center; NCI, National Cancer Institute; ORR, overall response rate; OS, overall survival; SCRI, Seattle Children’s Research Institute; UPenn, University of Pennsylvania.